FAILED TRIAL: Ph 3 LEAP-001 Trial of KEYTRUDA + LENVIMA as 1L Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma did not meet primary dual endpoints December 11, 2023
New Preliminary OS data in Selinexor-Treated Patients with Advanced or Recurrent TP53 WT Endometrial Cancer from the SIENDO Study Announced December 4, 2023
Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient Population Announced December 4, 2023
Ph 3 RUBY trial of Jemperli + chemotherapy meets OS endpoint in patients with primary advanced or recurrent endometrial cancer November 7, 2023
EMA accepted the MAA for mirvetuximab soravtansine (ELAHERE®) for the treatment of patients with FRα-positive, platinum-resistant epithelial ovarian cancer October 31, 2023
Daiichi Sankyo and Merck Announce Global Development and Commercialization Collaboration for Three Daiichi Sankyo DXd ADCs October 25, 2023
Positive CHMP opinion recommending approval of Jemperli (dostarlimab) + chemo as 1L treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer October 25, 2023
Specialised Therapeutics signs exclusive license agreement with CanariaBio for new ovarian cancer therapy October 18, 2023
FDA Grants Priority Review to KEYTRUDA + Concurrent ChemoRT as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer October 11, 2023
Fast Track Designation for IDE161, for Treatment of Pretreated, Platinum-Resistant Advanced or Metastatic Ovarian Cancer Patients with BRCA1/2 Mutations October 3, 2023
Collaborative Trial to Study PP2A Inhibitor, LB-100, Plus Dostarlimab, in Clear-Cell Ovarian Cancer announced September 26, 2023
FDA Grants Priority Review to KEYTRUDA + Concurrent ChemoRT as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer September 26, 2023
TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved OS in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy September 13, 2023
FAILED TRIAL: Ph 3 INNOVATE-3 trial of TTFields + paclitaxel in patients with platinum-resistant ovarian cancer did not meet its primary endpoint of OS September 6, 2023
FAILED TRIAL: Ph 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer failed to meet primary endpoint of PFS improvement August 9, 2023
Jemperli (dostarlimab) + chemo approved in the US as 1L treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer August 9, 2023
Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization Announced August 2, 2023
Ph 3 KEYNOTE-A18 Trial Met Primary Endpoint of PFS in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer July 27, 2023
Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer Announced July 11, 2023
